<DOC>
	<DOCNO>NCT02474537</DOCNO>
	<brief_summary>This phase I , multi-center , open-label , single oral dose , parallel group study evaluate pharmacokinetics safety INC280 non-cancer subject impair hepatic function non-cancer subject normal hepatic function.The study population healthy male postmenopausal sterile female subject meet inclusion none exclusion criterion . Subjects assign group accord hepatic function : normal ( Group 1 ) , mild ( Group 2 ) , moderate ( Group 3 ) , severe ( Group 4 ) impairment . This study consist two-staged design interim analysis . In Stage 1 , subject Groups 1 , 2 3 enrol . Upon completion Stage 1 , interim analysis conduct . Depending result analysis , either study conclude enrollment Stage 2 commence enrollment Group 4 . A minimum 6 evaluable subject per group enrolled.Once enrol study , participant confine facility 4 day , give single dose INC280 monitor pharmacokinetic safety assessment .</brief_summary>
	<brief_title>INC280 Healthy Subjects With Impaired Hepatic Function Subjects With Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Inclusion Criteria ( group ) : Female subject must postmenopausal sterile Good health , determine absence clinically significant finding medical history , physical examination , vital sign , ECGs , unless consistent know clinical disease hepatic impairment subject Adequate organ function normal laboratory test , unless consistent know clinical disease hepatic impairment subject Body Mass Index ( BMI ) 18 36 kg/m2 , body weight ≥ 50 kg Inclusion Criteria ( hepatic impairment group ) : Confirmed liver disease Stable comorbidities allow long generally consider healthy Subjects hepatic impairment must meet following laboratory value : Aspartate transaminase ( AST ) ≤ 5 x ULN Alanine transaminase ( ALT ) ≤ 5 x ULN Total bilirubin ≤ 3 x ULN ( ≤ 5 x XULN subject severe hepatic impairment [ group 4 ] ) Calculated creatinine clearance ( use CockcroftGault formula ) ≥ 45 mL/min Platelets &gt; 40 x 10e9/L Exclusion Criteria ( group ) : History presence clinically significant ECG abnormality clinically significant cardiovascular disease Immunocompromised subject , include HIV Use drug know affect CYP3A4 Use QTprolonging drug Use drug , unless require treat hepatic impairment subject 's disease Use proton pump inhibitor ( PPI ) medication within 7 day prior dose current study last day confinement Exclusion Criteria ( normal hepatic function group ) : A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result Exclusion Criteria ( hepatic impairment group ) : Active Grade 3 4 hepatic encephalopathy within 4 week study entry Clinical evidence severe ascites Ascites require paracentesis within 3 week prior dose Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hepatic impairment ,</keyword>
	<keyword>INC280 ,</keyword>
	<keyword>Oral cMET Inhibitor ,</keyword>
	<keyword>Non-Cancer</keyword>
</DOC>